Background: E-cadherin is a well known tumor suppressor and its dysregulated expression correlates with tumor differentiation, metastasis and survival in esophageal squamous cell carcinoma (ESCC). p120 catenin is an Armadillo protein normally bound to E-cadherin in the cadherin-catenin complex at the adherens junction. Dysregulated expression and mislocalization of p120ctn affect its protective function of the complex. The objective of the present study was to evaluate the clinical significance of E-cadherin and p120ctn expression in ESCC.
INTRODUCTION
Esophageal cancer is the sixth most frequent cause of cancer death in the world. Among all histological subtypes, squamous cell carcinoma (ESCC) is the commonest one in Asia and locally in Hong Kong. 1 Unfortunately, the overall prognosis remains relatively poor, mostly because of late diagnosis, the propensity of early spread of disease, and its occurrence in a group of elderly patients with co-morbid illnesses. The identification of a sensitive and representative disease marker is important for prognostication and to guide appropriate treatment. 2 E-cadherin is a 120kDa transmembrane glycoprotein belonging to the superfamily of Ca 2+ -dependent cell adhesion molecules. It is mainly found in epithelial cells and plays a key role in cell-cell interaction. Normally E-cadherin functions as a mediator for tight intercellular adhesion, cell polarity and tissue architecture maintenance. 3 It is also a well known tumor suppressor and downregulation of protein expression has been reported in many cancers including gastric, colorectal, breast and bladder cancers. [4] [5] [6] [7] [8] [9] [10] [11] [12] Genetic mutations, loss of heterozygosity and hypermethylation of its promoter are some factors causing dysregulated E-cadherin expression in carcinomas. 13, 14 In ESCC, reduced E-cadherin expression has been reported to correlate with tumor differentiation, metastasis and prognosis. [15] [16] [17] [18] [19] [20] [21] p120 catenin (p120ctn) was first identified to be an efficient tyrosine kinase substrate 22 p120ctn is ubiquitously expressed at high levels bound to E-cadherin on the plasma membrane directly at the juxtamembrane domain (JMD). It regulates cadherin turnover at the cell surface and its dissociation promotes cadherin internalization. It also stabilizes E-cadherin and rescues its function post-translationally. 23 Besides cellular adhesive function, p120ctn is also involved in the regulation of cell motility through actin cytoskeleton remodeling via Rho, Rac and Cdc42 GTPases. [24] [25] [26] [27] Recent studies indicated that p120ctn downregulation was correlated with poorly differentiated tumor and metastatic phenotype in certain cancers. 12, 28, 29 The purpose of the present study was to evaluate the clinical significance of E-cadherin and p120ctn expression and their inter-relationship in prognostication of ESCC.
MATERIALS AND METHODS

Patients and Specimens
Seventy-one patients with esophageal squamous cell cancers (ESCC) who underwent esophagectomy between 1997 and 2005 at the Department of Surgery, University of Hong Kong Medical Centre, Queen Mary Hospital, Hong Kong were recruited in this study.
There were 50 men and 21 women; the mean age of the subjects was 65.0 ± 11.4 years (range 40 -87 years). None of these patients had received neo-adjuvant chemotherapy or radiotherapy. Patient demographics and data concerning their operation, histopathology, and long-term follow-up data were captured in a prospectively collected database.
Specimens of the primary tumor and non-tumor tissues from the proximal resection margins were obtained for storage and analyses.
Macroscopically, the site and size of the primary tumors were recorded. Standard blocks were taken and fixed in 10% formalin followed by embedding in paraffin wax. Histological sections were cut at 4μm and stained with hematoxylin and eosin for light microscopy.
Stained sections were reviewed and classified into different grades by the World Health Organization (WHO) criteria. The cancers were staged according to TNM classification. 30 Representative blocks from the tumor and non-tumor tissue from each specimen were chosen for immunohistochemical study.
Immunohistochemistry
Both tumor and non-tumor tissue blocks were cut into 4μm-thick sections and mounted on glass slides. Immunohistological staining was performed using the EnVision method as described previously. 31 Briefly, the sections were deparaffinized and rehydrated. Antigens 
Immunohistochemistry Evaluation
Tissue sections were assessed by light microscopy by a pathologist (AKYL). The grading of immunoreactivity was conducted according to staining intensity of tumor section compared with that of the corresponding non-tumor tissue. Staining intensity was classified into two categories: (a) complete loss / reduced expression and (b) preserved staining.
Specifically for p120ctn staining activity, localization of the protein antigen was also documented and was classified as (a) absent / reduced membranous staining or (b) preserved membranous staining.
Statistical Analysis
χ 2 test or Fisher's exact probability test was used to assess the association between immunohistochemical reactivity and clinicopathological characteristics. The Kaplan-Meier method was employed for survival analysis and differences in survival were estimated using the log rank test. A P value less than 0.05 was considered statistically significant. All the statistical analyses were performed using SPSS 13.0 for Windows (Chicago, IL, USA).
RESULTS
Expression of E-cadherin and p120ctn in esophageal squamous cell carcinomas
E-cadherin was mainly observed on the cell membrane of both non-tumor and tumor tissues ( Fig. 1 A & C) . Complete loss or reduced E-cadherin expression was detected in 42.3% (30/71) of ESCC patients. On the other hand, p120ctn expression was well preserved in the majority of ESCC patients (91.5%, 65/71). Unlike E-cadherin, it was found on both cell membrane and cytoplasm of non-tumor cells ( Fig. 1 B) . Absent or reduced membranous p120ctn was observed in 33.8% (24/71) of ESCC patients ( Fig. 1 D) .
Relationship between E-cadherin and p120ctn expression and localization
p120ctn membranous localization was related to membranous expression of E-cadherin.
When p120ctn was found on cell membrane, preserved membranous expression of E-cadherin was observed in 34 of 47 (72.3%) of patients. But when p120ctn was lost or accumulated in cytoplasm, membranous expression of E-cadherin was only found in 7 or had direct effect on membranous expression of E-cadherin.
Relationship between expression of E-cadherin and tumor differentiation in ESCC
Preservation of E-cadherin was noted in all well differentiated ESCC cases (100%, 12/12). In contrast, E-cadherin was lost or detected at low levels in most of the poorly differentiated ESCC patients (73.3%, 11/15). A trend of increasing number of E-cadherin preserved cases from poorly to well differentiated cancer patients was observed.
Heterogeneous expression pattern was also detected in the regions of squamous dysplasia ( Fig. 1 E) . A significant relationship was found between E-cadherin expression and ESCC tumor differentiation (P=0.001) ( Table 2) .
Relationship between localization of p120ctn and tumor differentiation in ESCC
Two of 12 well differentiated ESCC patients (8.3%) were found to have membranous loss of p120ctn from membrane to cytoplasm. The p120ctn mislocalization was detected in the poorly and moderately differentiated cases in 91.7%, (22/24). Among cases with preserved membranous p120ctn protein, 89.4% (42/47) had moderately or well differentiated tumors. Both gradual decrease in expression and increase in mislocalization of p120ctn protein were seen in squamous dysplasia (Fig. 1 F) . Thus the localization of p120ctn significantly correlated with tumor differentiation in ESCC (P=0.008) ( Table 3) .
Relationship between p120ctn expression and lymph node metastasis
Among all the patients with preserved p120ctn expression, 66.2% (43/65) showed lymph node metastases (N1). In the cases with either complete loss or reduction in the expression of p120ctn, none (0%, 0/6) had lymph node metastasis (p=0.003).
Relationship between E-cadherin and p120ctn expression and localization and clinicopathological features
No statistical significant relationship was found when E-cadherin and p120ctn expression and localization were correlated with other clinicopathological features including age, gender, smoking status, level of tumor, R category, pathological T-stage and M-stage, as well as pathological stage (Tables 2 & 3) .
Relationship between E-cadherin and p120ctn expression and localization and survival
There were no significant differences in survival when patients were grouped and compared according to E-cadherin expression, p120ctn expression and p120ctn localization (P=0.927; P=0.700 and P=0.183 respectively) ( Fig. 2 A, B & C) . All three factors had no significant predictive value in ESCC patient survival.
DISSCUSSION
In the present study, we demonstrated that membranous expression of E-cadherin and p120ctn was found in non-tumor tissues of the esophagus, but complete loss or reduction of E-cadherin expression was shown in 42.3% of ESCC tumors. This is similar to other cancers previously reported. 8, 11, 21, 32 The reduced E-cadherin protein expression was associated with tumor differentiation (P=0.001) but not the other clinicopathological parameters that were analyzed. In previous studies, downregulated E-cadherin expression was also observed according to the decreasing degree of tumor differentiation in ESCC. 15, 16 In esophageal adenocarcinoma, heterogeneous staining pattern with gradually diminishing expression of E-cadherin was seen from regions of metaplasia to dysplasia and to carcinoma, which indicated that the reduction of E-cadherin expression might also play a role in tumor progression in ESCC. 33 In the present study on ESCC, heterogeneous expression of E-cadherin was also noted in dysplastic mucosa adjacent to the carcinoma. E-cadherin expression is associated with higher metastatic rate in colorectal cancer, ESCC and head and neck squamous cell carcinoma. 8, 19, 34, 35 However, we could not demonstrate any significant relationship between E-cadherin expression level and lymph node metastasis (P=0.332). It is worth noting that expression of N-cadherin promotes cell motility, invasion and metastasis even in the presence of high level of E-cadherin in breast cancer. 10, 36 Thus, other cadherins such as N-cadherin may participate in intercellular adhesion compensating the loss of E-cadherin function. 11 Another reason for the preserved level of E-cadherin in ESCC with lymph node metastasis might be the detected proteins were the mutant with a larger molecular weight but no cell-cell adhesion ability. 37 p120ctn normally binds to the juxtamembrane domain (JMD) of E-cadherins exerting a stabilizing effect in normal tissue. 23 In earlier studies, p120ctn protein was detected in cell-cell boundaries in benign tumors and normal tissues but in cytoplasm in carcinomas. 9, 28, 38 In our IHC results, it did not show an overall decreased expression of p120ctn in most of the ESCC cases, but absent or decreased membranous expression and cytoplasmic accumulation were observed. Since p120ctn is a metabolically stable protein, its expression and half-life are not affected by the absence of cadherins and that might be the reason why our findings did not show a significant relationship between E-cadherin expression and p120ctn expression (P=0.233) (Data not shown). [39] [40] [41] In this study, mislocalization of p120ctn from cell membrane to cytoplasm was significantly associated with the loss or reduction in membranous E-cadherin in ESCC (P=0.001). Recently, there were two proposed mechanisms to explain such a relationship.
First, mislocalization of p120ctn in cytoplasm leads to its incapability of interacting with E-cadherin, and consequently loses its protective effect, and eventually internalization and degradation of membranous E-cadherin. 41 Membranous derangement of p120ctn might be due to the p120ctn-microtubule network association directly or indirectly through the interaction with kinesin, 42 or an increased δ-catenin pool which competes with p120ctn for the JMD on cadherins. 43 Second is the insufficient capture of cytoplasmic p120ctn to cell membrane by downregulated E-cadherin leading to accumulation of excess p120ctn in the cytoplasm. 9, 35 In this study, p120ctn overall expression was preserved in all pathological N1 ESCC cases. This is in contrast to the findings of Bremnes et al. for lung cancer. 29 It may be due to the fact that our samples are of a different cancer type by which it is not comparable as p120ctn expression is tissue and cell type specific. 44 In addition, it has been suggested that different isoforms of p120ctn might display different functions. Aho and colleagues showed that certain isoforms of p120ctn did not induce branching phenotype while others did.
Isoforms 4A and 1AB might have tumor-suppressor roles in skin cancer. 45 Herein, we used a primary antibody which recognized all 4 isoforms of p120ctn and therefore all detected proteins were indistinguishable. The differential expression profiles of different isoforms might account for the unexpected different results. It might also explain why there was no apparent significant relationship between p120ctn localization and pathological N-stage even though we understood that the p120ctn-uncoupled E-cadherin was vulnerable to endocytosis and hence losing its cell-cell adhesive ability. p120ctn has been reported as an independent prognostic marker in gastroesophageal adenocarcinoma. 28 In the present study, p120ctn localization in ESCC showed a significant relationship with tumor differentiation (P=0.008). Membranous p120ctn protein was mostly preserved in well differentiated tumors but lost or reduced in poorly differentiated ones. It is also present occasionally in dysplastic mucosa, indicating that p120ctn localization might take part in tumor progression. However, no significant relationship between p120ctn expression and survival rate was noted in ESCC.
In conclusion, E-cadherin expression and p120ctn localization were associated with ESCC tumor differentiation, and in addition, p120ctn expression was related to lymph node metastasis. To our knowledge, this was the first time that a significant relationship between 
